BeOne Medicines reports in an SEC filing that Q2 2026 revenue rose 30% to $1.7 billion and raises full-year guidance to $6.6–$6.8 billion
https://finviz.com/stock?t=ONC&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.